CTX 310
Alternative Names: CTX-310Latest Information Update: 26 Dec 2023
At a glance
- Originator CRISPR Therapeutics
- Class Cardiovascular therapies; Gene therapies; Vascular disorder therapies
- Mechanism of Action ANGPTL3 protein expression modulators; Gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Cardiovascular disorders
- Preclinical Atherosclerosis
Most Recent Events
- 11 Nov 2023 Pharmacodynamics data from preclinical studies in cardiovascular disorders presented at the American Heart Association Scientific Sessions 2023 (AHA-2023)
- 06 Nov 2023 Phase-I clinical trials in Cardiovascular disorders (Parenteral)
- 06 Nov 2023 Pharmacodynamics and adverse events data from a preclinical trial in Atherosclerosis released by CRISPR Therapeutics